Healthcare company Novo Nordisk (NVO) has reported promising results from its latest clinical trial for its obesity treatment. Notably, tripling the drug’s dose helped patients achieve significantly more weight loss, strengthening the company’s position as it competes with U.S. rival Eli Lilly (LLY) in the growing obesity treatment market. Following the trial results, Novo’s U.S.-listed shares were up 1% in …
Read More »Novo Nordisk Stock (NVO) Rises After Triple-Dose Trial Hits 19% Weight Loss
